about
P-glycoprotein modulates morphine uptake into the CNS: a role for the non-steroidal anti-inflammatory drug diclofenacEffects of hypoxia-reoxygenation on rat blood-brain barrier permeability and tight junctional protein expression.Effect of reduced flow on blood-brain barrier transport systems.Nicotine increases in vivo blood-brain barrier permeability and alters cerebral microvascular tight junction protein distribution.Peptide targeting and delivery across the blood-brain barrier utilizing synthetic triglyceride esters: design, synthesis, and bioactivity.Smoking and ischemic stroke: a role for nicotine?Stroke: development, prevention and treatment with peptidase inhibitors.Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation.Peptide fragments derived from the beta-chain of hemoglobin (hemorphins) are centrally active in vivo.Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability.Inflammatory pain signals an increase in functional expression of organic anion transporting polypeptide 1a4 at the blood-brain barrierCharacterization of HIV-1 envelope gp41 genetic diversity and functional domains following perinatal transmission.Permeability of the blood-brain barrier to peptides: an approach to the development of therapeutically useful analogs.Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood-brain barrier during inflammatory painAn activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations.CNS drug delivery: opioid peptides and the blood-brain barrierTargeted drug delivery to treat pain and cerebral hypoxiaNociceptive inhibition prevents inflammatory pain induced changes in the blood-brain barrier.An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway.Strategies to advance translational research into brain barriers.Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity.Chronic inflammatory pain and the neurovascular unit: a central role for glia in maintaining BBB integrity?Acetaminophen modulates P-glycoprotein functional expression at the blood-brain barrier by a constitutive androstane receptor-dependent mechanismP-glycoprotein trafficking at the blood-brain barrier altered by peripheral inflammatory hyperalgesia.Biphasic cytoarchitecture and functional changes in the BBB induced by chronic inflammatory painVolume and composition of hand sweat of White and Black men and women in desert walks.Assessment of stereoselectivity of trimethylphenylalanine analogues of delta-opioid [D-Pen(2),D-Pen(5)]-enkephalin.Improved analogs and novel delivery systems for somatostatin octapeptides.Ectoenzymes as sites of peptide regulation.Differential modulation of prohormone convertase mRNA by second messenger activators in two cholecystokinin-producing cell lines.Modulation of CCK mRNA in cell lines in response to isoproterenol and retinoic acid.Second messenger activators regulate CCK mRNA in the human neuroepithelioma cell line SK-N-MCIXC.Regulation of CCK mRNA in the human neuroepithelioma cell line SK-N-MCIXC in response to second messenger activators.Specificity of neurotensin metabolism by regional rat brain slices.Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant's anticoagulant activity.Viability of microvascular endothelial cells to direct exposure of formalin, lambda-carrageenan, and complete Freund's adjuvant.Blood-brain barrier tight junctions are altered during a 72-h exposure to lambda-carrageenan-induced inflammatory pain.Pluronic p85 block copolymer enhances opioid peptide analgesia.Transport of opioid peptides into the central nervous system.
P50
Q28539683-3B565FA2-EB40-4E40-946C-083D6B06BD94Q31153090-F60F216F-7402-4B3F-9610-99D4F49E65B4Q31871636-8A9FBD61-A452-4FA8-8EA8-F623552D967AQ33982428-4958D506-167A-4B5F-A67A-C799FCCC5845Q34064737-F9A3C7DA-B7D1-4B4E-B5AB-77BB973D8560Q34112876-2A9BF0DA-BCDA-4868-B2F4-FBE77C2F45ACQ34126251-72E532C6-1656-4436-8E84-C87C15B1CCCBQ34171371-44EF76CF-CAAF-4F9E-96A4-CB0B10EAFF5BQ34471695-ED56BF5F-4D11-4B3E-B00E-28D87CE71EDBQ34489836-E4B3E1FA-206D-4B6B-AA03-A6115987DD2BQ34702220-00523C0B-4462-4D38-99B6-689FF1447EC7Q34899225-7CF8AF62-A6B0-45D5-BF9C-0828589DAA65Q35665377-0CD81936-27F1-4E97-AC1E-42296F3F9206Q35964989-C80F3097-E876-4880-B716-1B957D25A900Q36195195-B7922BD1-5438-4999-8959-E670152EDD19Q36263489-6FA991A0-DD87-4A7C-BB79-CCD71B216762Q36439195-0750AF29-FA94-4EE7-9ACA-DAC620C1C0C8Q36591611-E12A32DF-46E9-4EDD-9300-8D8CFCC47311Q36974166-BEBA7122-2B1D-486E-835D-32E403E9B97CQ37000469-09F95E9F-40FC-4876-85AB-84EB9FE015A9Q37037950-5FA94A2C-03E4-4498-B0A8-B419B3A40332Q37214257-316130CF-BD7E-4AC5-9E83-D4F74FBC9490Q37232879-DC5CFC7A-E1E0-4CFB-86B5-13B5E710837DQ37252086-A62AC534-93A9-436A-AF82-08C67AD53E51Q37364487-5E00B56F-F3E6-4A30-8226-1A5695B71FF2Q37483383-D54E44DD-3051-4EC1-B28E-B673A6E71CE4Q38973347-7484BE30-460B-433D-8E9C-A156E8EE413EQ40760933-9A0659D1-6E60-4D1A-954A-523716D28AB6Q41081393-3B1640DA-A853-43CE-B85E-832C790D4F07Q41114566-40F8412B-B6A0-4556-8F93-3C0FF82013B5Q41248791-DDAF584D-058E-4AAF-97CE-C026DB283D18Q41286525-E2211464-80FA-40CC-8CB9-BEB94A356D00Q41480086-32980D6F-BC33-46F5-9FC3-6C05F8BD0400Q41513571-7754626F-2A8E-4AE1-91CB-C79E3E919BC8Q42145992-72C7B55E-0D0C-49EF-A44F-11554CC093ACQ42246927-4B3642B7-7018-4728-A81A-6F5C8D1CAE4FQ44123303-9B0FEC1A-C58E-4F8B-A9D1-FCB12C2043E5Q44138424-42C561BC-0C03-4A38-98A6-AAA7221B1F83Q44186098-BFBF2507-6A28-4A19-A906-8C45160FBF9CQ44350552-17B33FE6-A6CB-421A-BE24-0FEE817F2B00
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Thomas P Davis
@ast
Thomas P Davis
@en
Thomas P Davis
@es
Thomas P Davis
@nl
type
label
Thomas P Davis
@ast
Thomas P Davis
@en
Thomas P Davis
@es
Thomas P Davis
@nl
altLabel
thomas davis
@en
prefLabel
Thomas P Davis
@ast
Thomas P Davis
@en
Thomas P Davis
@es
Thomas P Davis
@nl
P1053
F-3244-2015
P106
P2038
Thomas_Davis3
P31
P496
0000-0001-8465-4973